Poor reporting of multivariable prediction model studies: Towards a targeted implementation strategy of the TRIPOD statement

BMC Medicine

Volumn 16, Issue 1, 2018, Pages

  Heus, Pauline ^a   Damen, Johanna A A G ^a   Pajouheshnia, Romin ^a   Scholten, Rob J P M ^a   Reitsma, Johannes B ^a   Collins, Gary S ^b   Altman, Douglas G ^b   Moons, Karel G M ^a   Hooft, Lotty ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Development; Diagnosis; Incremental value; Prediction model; Prediction rule; Prognosis; Reporting guideline; Risk assessment; Risk score; TRIPOD; Validation

Indexed keywords

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; HIGH RISK POPULATION; HUMAN; JOURNAL IMPACT FACTOR; MALE; MEDLINE; PRACTICE GUIDELINE; PREDICTION; PROGNOSIS; PUBLICATION; RISK ASSESSMENT; SYSTEMATIC REVIEW; VALIDATION PROCESS; METHODOLOGY;

HUMANS; PROGNOSIS; RESEARCH DESIGN;

EID: 85050260093     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/s12916-018-1099-2     Document Type: Article

References (35)

1. Steyerberg EW, Moons KG, van der Windt DA, Hayden JA, Perel P, Schroter S, et al. Prognosis Research Strategy (PROGRESS) 3: prognostic model research. PLoS Med. 2013;10(2):e1001381.
2. Altman DG, Vergouwe Y, Royston P, Moons KG. Prognosis and prognostic research: validating a prognostic model. BMJ. 2009;338:b605.
3. Moons KG, Kengne AP, Grobbee DE, Royston P, Vergouwe Y, Altman DG, et al. Risk prediction models: II. External validation, model updating, and impact assessment. Heart. 2012;98(9):691-8.
4. Moons KG, Kengne AP, Woodward M, Royston P, Vergouwe Y, Altman DG, et al. Risk prediction models: I. Development, internal validation, and assessing the incremental value of a new (bio)marker. Heart. 2012;98(9):683-90.
5. Royston P, Moons KG, Altman DG, Vergouwe Y. Prognosis and prognostic research: developing a prognostic model. BMJ. 2009;338:b604.
6. Collins GS, Mallett S, Omar O, Yu LM. Developing risk prediction models for type 2 diabetes: a systematic review of methodology and reporting. BMC Med. 2011;9:103.
7. Bouwmeester W, Zuithoff NP, Mallett S, Geerlings MI, Vergouwe Y, Steyerberg EW, et al. Reporting and methods in clinical prediction research: a systematic review. PLoS Med. 2012;9(5):1-12.
8. Collins GS, Omar O, Shanyinde M, Yu LM. A systematic review finds prediction models for chronic kidney disease were poorly reported and often developed using inappropriate methods. J Clin Epidemiol. 2013;66(3):268-77.
9. Collins GS, de Groot JA, Dutton S, Omar O, Shanyinde M, Tajar A, et al. External validation of multivariable prediction models: a systematic review of methodological conduct and reporting. BMC Med Res Methodol. 2014;14:40.
10. Damen JA, Hooft L, Schuit E, Debray TP, Collins GS, Tzoulaki I, et al. Prediction models for cardiovascular disease risk in the general population: systematic review. BMJ. 2016;353:i2416.
11. Wen Z, Guo Y, Xu B, Xiao K, Peng T, Peng M. Developing risk prediction models for postoperative pancreatic fistula: a systematic review of methodology and reporting quality. Indian J Surg. 2016;78(2):136-43.
12. Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): the TRIPOD statement. Ann Intern Med. 2015;162(1):55-63.
13. Moons KG, Altman DG, Reitsma JB, Ioannidis JP, Macaskill P, Steyerberg EW, et al. Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration. Ann Intern Med. 2015;162(1):W1-73.
14. 2012 Journal Citation Reports In: Science edition.Philadelphia: Clarivate Analytics; 2017.
15. Ingui BJ, Rogers MA. Searching for clinical prediction rules in MEDLINE. J Am Med Inform Assoc. 2001;8(4):391-7.
16. Moons KG, Royston P, Vergouwe Y, Grobbee DE, Altman DG. Prognosis and prognostic research: what, why, and how? BMJ. 2009;338:b375.
17. Riley RD, Hayden JA, Steyerberg EW, Moons KG, Abrams K, Kyzas PA, et al. Prognosis Research Strategy (PROGRESS) 2: prognostic factor research. PLoS Med. 2013;10(2):e1001380.
18. Chalmers I, Glasziou P. Avoidable waste in the production and reporting of research evidence. Lancet. 2009;374(9683):86-9.
19. Glasziou P, Altman DG, Bossuyt P, Boutron I, Clarke M, Julious S, et al. Reducing waste from incomplete or unusable reports of biomedical research. Lancet. 2014;383(9913):267-76.
20. Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux PJ, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c869.
21. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med. 2010;152(11):726-32.
22. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig L, et al. STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies. BMJ. 2015;351:h5527.
23. Cohen JF, Korevaar DA, Altman DG, Bruns DE, Gatsonis CA, Hooft L, et al. STARD 2015 guidelines for reporting diagnostic accuracy studies: explanation and elaboration. BMJ Open. 2016;6(11):e012799.
24. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer. 2005;93(4):387-91.
25. Moher D, Jones A, Lepage L. Use of the CONSORT statement and quality of reports of randomized trials: a comparative before-and-after evaluation. JAMA. 2001;285(15):1992-5.
26. Korevaar DA, van Enst WA, Spijker R, Bossuyt PM, Hooft L. Reporting quality of diagnostic accuracy studies: a systematic review and meta-analysis of investigations on adherence to STARD. Evid Based Med. 2014;19(2):47-54.
27. Mallett S, Timmer A, Sauerbrei W, Altman DG. Reporting of prognostic studies of tumour markers: a review of published articles in relation to REMARK guidelines. Br J Cancer. 2010;102(1):173-80.
28. Sekula P, Mallett S, Altman DG, Sauerbrei W. Did the reporting of prognostic studies of tumour markers improve since the introduction of REMARK guideline? A comparison of reporting in published articles. PLoS One. 2017;12(6):e0178531.
29. Hopewell S, Dutton S, Yu LM, Chan AW, Altman DG. The quality of reports of randomised trials in 2000 and 2006: comparative study of articles indexed in PubMed. BMJ. 2010;340:c723.
30. Korevaar DA, Wang J, van Enst WA, Leeflang MM, Hooft L, Smidt N, et al. Reporting diagnostic accuracy studies: some improvements after 10 years of STARD. Radiology. 2015;274(3):781-9.
31. Smidt N, Rutjes AW, van der Windt DA, Ostelo RW, Bossuyt PM, Reitsma JB, et al. The quality of diagnostic accuracy studies since the STARD statement: has it improved? Neurology. 2006;67(5):792-7.
32. Turner L, Shamseer L, Altman DG, Weeks L, Peters J, Kober T, et al. Consolidated Standards of Reporting Trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals. Cochrane Database Syst Rev. 2012;11:Mr000030.
33. Chan AW, Altman DG. Epidemiology and reporting of randomised trials published in PubMed journals. Lancet. 2005;365(9465):1159-62.
34. Moher D, Schulz KF, Simera I, Altman DG. Guidance for developers of health research reporting guidelines. PLoS Med. 2010;7(2):e1000217.
35. Heus P, Hooft L, Reitsma JB, Scholten RJPM, Altman DG, Collins GS, et al. Reporting of clinical prediction model studies in journal and conference abstracts: TRIPOD for Abstracts. In: 24th Cochrane Colloquium; 2016 23-27 Oct: 2016. Seoul: Wiley; 2016.